^
    Back
    Association details:
    Biomarker:MLL translocation
    Cancer:Acute Myelogenous Leukemia
    Drug:birabresib (OTX015) (BRD4 inhibitor, BRD2 inhibitor, BRD3 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    ASH 2019
    Title:

    The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

    Published date:
    11/06/2019
    Excerpt:
    MLL-translocated patients displaying a homozygous and compound heterozygous MTHFR genotype for any of the two variants (n=8) responded significantly less to OTX015 than those with wild-type homozygous and heterozygous MTHFR genotypes (n=8).
    DOI:
    https://doi.org/10.1182/blood-2019-131255